Bettina M Cockroft Selected Research

reldesemtiv

1/2023	COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
1/2022	Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.
7/2021	Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
1/2021	Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
1/2021	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bettina M Cockroft Research Topics

Disease

2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2023 - 01/2021
2	Disease Progression 01/2023 - 01/2022
2	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 07/2021 - 01/2021
1	Hemophilia A (Haemophilia) 10/2023
1	Hemorrhage 10/2023
1	Nausea 01/2021
1	Fatigue 01/2021

Drug/Important Bio-Agent (IBA)

5	reldesemtivIBA 01/2023 - 01/2021
1	Hemostatics (Antihemorrhagics)IBA 10/2023
1	Factor VIII (Coagulation Factor VIII)IBA 10/2023
1	TroponinIBA 01/2021